Senescence is a stable growth arrest that impairs the replication of damaged, old or preneoplastic cells, therefore contributing to tissue homeostasis. Senescent cells accumulate during ageing and are associated with diseases, such as cancer, fibrosis and many age-related pathologies. Recent evidence suggests that the selective elimination of senescent cells can be effective on the treatment of many of these senescence-associated diseases. A universal characteristic of senescent cells is that they display elevated activity of the lysosomal b-galactosidase this has been exploited as a marker for senescence (senescence-associated b-galactosidase activity). Consequently, we hypothesised that galactose-modified cytotoxic prodrugs will be preferentially processed by senescent cells, resulting in their selective killing. Here, we show that different galactose-modified duocarmycin (GMD) derivatives preferentially kill senescent cells. GMD prodrugs induce selective apoptosis of senescent cells in a lysosomal b-galactosidase (GLB1)-dependent manner. GMD prodrugs can eliminate a broad range of senescent cells in culture, and treatment with a GMD prodrug enhances the elimination of bystander senescent cells that accumulate upon whole body irradiation or doxorubicin treatment of mice. Moreover, taking advantage of a mouse model of human adamantinomatous craniopharyngioma (ACP), we show that treatment with a GMD pro-drug result selectively reduced the number of b-cateninpositive preneoplastic senescent cells, what could have therapeutic implications. In summary, the above results show that galactose-modified duocarmycin prodrugs behave as senolytics, suggesting that they could be used to treat a wide range of senescence-related pathologies. Guerrero et al. 4 
SUMMARY
Senescence is a stable growth arrest that impairs the replication of damaged, old or preneoplastic cells, therefore contributing to tissue homeostasis. Senescent cells accumulate during ageing and are associated with diseases, such as cancer, fibrosis and many age-related pathologies. Recent evidence suggests that the selective elimination of senescent cells can be effective on the treatment of many of these senescence-associated diseases. A universal characteristic of senescent cells is that they display elevated activity of the lysosomal b-galactosidase this has been exploited as a marker for senescence (senescence-associated b-galactosidase activity). Consequently, we hypothesised that galactose-modified cytotoxic prodrugs will be preferentially processed by senescent cells, resulting in their selective killing. Here, we show that different galactose-modified duocarmycin (GMD) derivatives preferentially kill senescent cells. GMD prodrugs induce selective apoptosis of senescent cells in a lysosomal b-galactosidase (GLB1)-dependent manner. GMD prodrugs can eliminate a broad range of senescent cells in culture, and treatment with a GMD prodrug enhances the elimination of bystander senescent cells that accumulate upon whole body irradiation or doxorubicin treatment of mice. Moreover, taking advantage of a mouse model of human adamantinomatous craniopharyngioma (ACP), we show that treatment with a GMD pro-drug result selectively reduced the number of b-cateninpositive preneoplastic senescent cells, what could have therapeutic implications. In summary, the above results show that galactose-modified duocarmycin prodrugs behave as senolytics, suggesting that they could be used to treat a wide range of senescence-related pathologies.
INTRODUCTION
Cellular senescence is a stress response that prevents the replication of old, damaged or transformed cells . Senescence can be induced by replicative exhaustion and also by a range of insults that includes oncogenic activation, genotoxic stress or irradiation. The defining feature of senescence is a stable cell cycle arrest, but senescent cells also undergo multiple phenotypic changes including alterations in their morphology, metabolic state or chromatin arrangement (Salama et al. 2014) . In particular, senescent cells secrete a combination of extracellular factors, the so-called senescenceassociated secretory phenotype or SASP, which is a prominent mediator of the pathophysiological effects of senescence (Kuilman & Peeper 2009; Coppe et al. 2010) .
Despite that the acute induction of senescence limits fibrosis and protects against cancer progression, the abnormal accumulation of senescent cells with age or in diseased tissues is considered detrimental (Munoz-Espin & Serrano 2014) . Interestingly, recent evidences drawn from genetic models have shown that eliminating senescent cells increases lifespan, improves healthspan and benefits the outcomes of a wide range of diseases (Baker et al. 2011; Baker et al. 2016; Childs et al. 2016; Childs et al. 2017) . These studies have led to a collective effort to identify 'senolytics', drugs that selectively kill senescent cells. Several senolytics have been identified including dasatinib and quercetin , piperlongumine , FOXO4 interfering peptides (Baar et al. 2017) , HSP90 inhibitors (Fuhrmann-Stroissnigg et al. 2017) or the Bcl2 family inhibitors ABT-263 (navitoclax) and ABT-737 (Chen et al. 2015; Yosef et al. 2016; Zhu et al. 2016) . Currently, Bcl2 family inhibitors have become the gold-standard on senolysis. Bcl2 family inhibitors eliminate a range of senescent cells in vivo and reproduce the effects observed in transgenic mice modelling senescence ablation (Ovadya & Krizhanovsky 2018) . However, ABT-263, causes severe thrombocytopenia and neutropenia, what might complicate its use on the clinic. Moreover, it is becoming evident than different senolytics might be necessary to eliminate different types of senescent cells. Therefore, there is a need to identify additional drugs with senolytic properties.
An alternative strategy for targeting senescence, is to exploit properties that differentiate senescent from normal cells. In this regard, the senescence-associated b-galactosidase activity (SA-b-gal) is one of the more conserved and defining characteristics of senescent cells. Senescent cells present an increased lysosomal mass (Kurz et al. 2000) . As a result, senescent cells display elevated levels of lysosomal enzymes such as b-galactosidase (encoded by GLB1, (Dimri et al. 1995) ) or a-fucosidases (Hildebrand et al. 2013) . Indeed, it has been shown that galacto-oligosacharide encapsulated nanoparticles (GalNP) preferentially release their content on senescent cells (Agostini et al. 2012) . Consequently, this GalNP can be used in combination with different cargos to either image or kill senescent cells (Munoz-Espin et al. 2018) .
Galactose-modification has been frequently used to improve the pharmacokinetic properties or the delivery of existing drugs. In addition, galactose modification can be used to generate pro-drugs that rely on E. coli b-galactosidase for controlled activation (Melisi et al. 2011) .
When combined with antibody-linked b-galactosidase, this approach is known as antibodydirected enzyme prodrug therapy (ADEPT), (Bagshawe 2006; Tietze & Schmuck 2011) . In ADEPT, a conjugate of a tumour-specific antibody and an enzyme, such as b-galactosidase, is combined with the application of a hardly cytotoxic prodrug. By means of the enzyme in the conjugate, the prodrug is selectively cleaved in cancer cells leading to the formation of a highly cytotoxic compound. Several of these galactose-modified cytotoxic prodrugs have been described (Leenders et al. 1999) . A class of such prodrugs are galactose-modified duocarmycin (GMD) derivatives (Tietze et al. 2006) . Duocarmycins are a group of antineoplastic agents with low picomolar potency. They are thought to act by binding and alkylating double stranded DNA in AT-rich regions of the minor groove, (Boger et al. 1994; Tietze et al. 2006; Tietze et al. 2009 ), but alternative mechanisms of action have been proposed to account for the cytotoxic effects of duocarmycin dimers (Wirth et al. 2012) .
Here, we investigated whether galactose-modified prodrugs can preferentially kill senescent cells. We have assessed the senolytic potential of several GMD derivatives and confirmed their senolytic potential in cell culture, ex vivo and in vivo. Given the increasing list of senescence-associated diseases and the positive effects associated with senolytic treatment, we propose GMD derivatives and more generally galactose-modified prodrugs are a new class of senolytic compounds with wide therapeutic promise.
RESULTS

A galactose-modified duocarmycin prodrug with senolytic properties.
The natural antibiotic duocarmycin is a highly cytostatic compound (Boger & Johnson 1995) .
A series of glycosidic derivatives of duocarmycin have been previously developed to be used as prodrugs in the context of antibody-directed enzyme prodrug therapy (ADEPT) (Tietze et al. 2009; Tietze et al. 2010) . Given that senescent cells display elevated levels of SA-b-Galactosidase activity, we hypothesize that galactose-modified cytotoxic prodrugs will be preferentially processed by senescent cells, resulting in their selective killing. To test this hypothesis, we took advantage of a galactose-modified duocarmycin (GMD) prodrug (referred as prodrug A) previously described (Tietze et al. 2009 ). We analysed the effects that a seco-duocarmycin analogue dimer (duocarmycin SA) and its galactose derivative (prodrug A) had on the survival of IMR90 ER:RAS cells, a model of oncogene-induced senescence (OIS). Activation of the ER:RAS fusion with 4-hydroxy-tamoxifen (4OHT) induces senescence in IMR90 ER:RAS cells (Georgilis et al. 2018) . Treatment with duocarmycin SA was equally effective in killing normal and senescent cells, with the exception of a small selectivity towards senescent cells at the lower concentrations (Fig 1a) .
In contrast, when we treated IMR90 ER:RAS cells with prodrug A (differing only in the addition of two galactose groups that inactivate it), we observed the preferential elimination of senescent cells (Fig 1b) . Duocarmycins are known to bind and alkylate DNA in AT-rich regions of the minor groove, and induce cell death in a way dependent of DNA replication (Boger et al. 1994; Tietze et al. 2006; Tietze et al. 2009 ) We checked that senescent cells were growth arrested at the time of the drug treatment (Sup Fig 1) . This shows that the effect observed is not due to hyperreplication of cells during early stages of OIS and suggest that the prodrug might act by some of the alternative cytotoxic mechanisms described for duocarmycin dimers (Wirth et al. 2012) . Treatment with prodrug A induced caspase 3/7 activity on senescent cells (Fig 1c) , and the selective death of this cells was prevented with a pan-caspase inhibitor (Fig 1d) . The above results suggest that GMD prodrugs can behave as senolytics by selectively inducing apoptosis on senescent cells.
Galactose-modified duocarmycin prodrugs are broad-spectrum senolytics.
To understand the extent to which GMD prodrugs behave as senolytics, we assessed the effect that prodrug A has on several types of senescent cells. To this end, we took advantage of IMR90 cells and induced senescence by etoposide or doxorubicin treatment, irradiation, or serial passage. In all those instances, treatment with prodrug A resulted in the selective elimination of senescent cells (Fig 2a-d) . Moreover, to evaluate whether the senolytic effects of prodrug A were restricted to IMR90 cells or also observed in other cell types, we took advantage of human mammary epithelial cells able to undergo OIS upon Ras activation (HMEC ER:RAS). Prodrug A was also able to selectively kill HMEC senescent cells (Fig 2e) , suggesting that its senolytic effects were not cell type restricted. Finally, we wanted to examine whether the senolytic properties were specific of prodrug A, or the general concept (conversion of other cytotoxic drugs in galactose-modified prodrugs) was wider. To this end we took advantage of two previously described GMD prodrugs, JHB76B and JHB35B, (Tietze et al. 2009; Tietze et al. 2010) . Both drugs were also effective in selectively eliminating senescent cells (Fig 2f and Sup Fig 2) , suggesting that generation of galactosemodified prodrugs might be a general route to design senolytic compounds.
Senolytic properties of prodrug A depend on the lysosomal b-galactosidase.
We had initially hypothesized that GMD prodrugs could behave as a senolytic due to the higher SA-b-Galactosidase activity of senescent cells. Increased b-Galactosidase on senescent cells is due to an increase in lysosomal mass (Kurz et al. 2000) resulting in higher activity of the lysosomal b-Galactosidase (encoded by GLB1) (Lee et al. 2006) . To understand if this was the case and senolytic activity of GMD prodrugs is dependent on SAb-Galactosidase, we took advantage of three independent shRNAs to knockdown GLB1.
Knockdown of GLB1 in IMR90 ER:RAS cells, resulted in decreased SA-b-Galactosidase activity, but it did not impact the growth arrest or the induction of p16 INK4a observed during OIS (Fig 3a-d ). Taking advantage of these cells, we observed that GLB1 knock down did not affect the senolytic potential of ABT-263 but ablated the ability of prodrug A to selectively kill senescent cells (Fig 3e) . In summary, our data suggests that GMD prodrugs trigger apoptosis of senescent cells in a GLB1-dependent manner.
Prodrug A eliminates bystander senescent cells in vivo.
Chemotherapy and radiotherapy are amongst the most common anti-cancer treatments.
Irradiation, chemotherapy and even some targeted anti-cancer drugs, all induce senescence (Schmitt et al. 2002; Wang et al. 2017) . Although induction of tumour senescence explains the anti-cancer properties of these treatments, the generation of bystander senescent cells is responsible for their side effects . To assess whether pro-drug A could eliminate these bystander senescent cells, we first irradiated mice and upon a latency period to allow for the accumulation of senescent cells, treated them with prodrug A, ABT263 or vehicle (Fig 4a) . Treatment with prodrug A or ABT-263 resulted in a reduced presence of senescent cells in lung as assessed using SA-b-Galactosidase activity (Fig 4b) .
Galactose-modified prodrugs eliminate preneoplastic senescent cells.
OIS is primarily considered as a tumour suppressive mechanism (Collado et al. 2005 ) but senescent cells present in the tumour microenvironment can also drive tumour progression (Gonzalez-Meljem et al. 2018) . We have previously demonstrated in mouse models of adamantinomatous craniopharyngioma (ACP), a pituitary paediatric tumour, that clusters of cells that accumulate nucleo-cytoplasmic b-catenin are senescent and drive tumour progression in a paracrine manner (Gonzalez-Meljem et al. 2017) . To understand if GMD prodrugs could eliminate these pro-tumourigenic senescent clusters, we used the Hesx1 Cre/+ ;Ctnnb1 lox(ex3)/+ ACP mouse model. Tumoural, cluster-containing embryonic pituitaries were cultured ex vivo with vehicle or prodrug A (Fig 5a) . Treatment with prodrug A preferentially eliminated the β-catenin-accumulating senescent cell clusters, without affecting other cell types in the pituitary such as synaptophysin + cells (Fig 5b-d ). Co-staining with an antibody recognizing cleaved caspase 3 showed that prodrug A predominantly induced apoptosis of senescent cluster cells (Fig 5e and Sup Fig 3) . The above results suggest that GMD prodrugs can be also used to eliminate preneoplastic senescent cells.
DISCUSSION
Recently, the use of genetic mouse models in which senescent cells can be ablated, has served to unveil important roles for senescence in health, disease and aging (Baker et al. 2011; Demaria et al. 2014; Baker et al. 2016) . Consequently, drugs have been identified that are able to phenocopy the effects of selectively eliminating senescent cells. Several of these so-called senolytic drugs have been discovered, with Bcl2 family inhibitors such as ABT-263 (navitoclax) and ABT-737 (Chen et al. 2015; Yosef et al. 2016; Zhu et al. 2016) being the prototypical examples.
Here, we add galactose-modified duocarmycin (GMD) prodrugs as a new class of senolytic agents. These GMD prodrugs are converted to their corresponding duocarmycin drugs in a manner dependent on processing by b-galactosidase. Since senescent cells display elevated levels of lysosomal b-galactosidase (encoded by GLB1), GMD selectively affect senescent cells. In this manuscript, we present evidence showing that GMD prodrugs can eliminate multiple types of senescent cells, what is consistent with SA-b-galactosidase being a universal marker of senescence. Moreover, we show that GMD prodrugs are also capable of eliminating bystander senescent cells caused by anti-cancer therapies and preneoplastic senescent cells in mouse models. Given the promise that senolytics present for the treatment of age-related disease, and their associated benefits over healthspan and lifespan, we believe that this study provides the basis to specifically assess the potential benefots of GMD on ageing.
Previously, the potential to harness the elevated b-galactosidase activity of senescent cells have been exploited with galacto-oligosaccharide encapsulated nanoparticles (GalNP) (Agostini et al. 2012 ). Combination of GalNP with different cargoes offers flexibility to image or eliminate senescent cells (Munoz-Espin et al. 2018 ). However, this flexibility comes to the expense of having to use a modular system, comprised of both the GalNP and the cargo.
Here, we propose the use of galactose-modified prodrugs in which a single molecule (the prodrug) is sufficient to target senescent cells taking advantage of their elevated bgalactosidase activity. While we show that duocarmycin derivatives behave as senolytic agents, this approach could be generalised to galactose-modified prodrugs derived of other cytotoxic agents.
In summary, we have described that galactose-modified duocarmycin prodrugs are a new class of broad-spectrum senolytic agents. We have characterized their ability to eliminate different types of senescent cells in culture and in vivo. Given the increasing list of diseases that are associated with senescence, galactose-modified duocarmycin prodrugs have the potential to be used in the context of anti-cancer therapies and to treat different age-related diseases.
EXPERIMENTAL PROCEDURES
Drugs. The following compounds were used in this study: ABT-263 (Selleckchem, S1001), Cell lines. IMR90 cells were obtained from ATCC. IMR90 ER:RAS and IMR90 ER:RAS cells expressing E6 and E7 proteins of HPV16 were generated by retroviral infection of IMR90 cells and have been described elsewhere Barradas et al. 2009 ). IMR90 were cultured in DMEM (Gibco) supplemented with 10% fetal bovine serum (Sigma) and 1% antibiotic-antimycotic solution (Gibco). HMEC were cultured in Medium 171 (Gibco) supplemented with MEGS (Gibco), 10% fetal bovine serum (Sigma) and 1% antibioticantimycotic solution (Gibco). To induce OIS, IMR90 ER:RAS and HMEC ER:RAS were treated with 100 nM 4-hydroxytamoxifen (4OHT, Sigma) reconstituted in DMSO. To induce chemotherapy-induced senescence, IMR90 cells were treated with 0.5 µM Doxorubicin (Sigma) for 24 hours, or with 50 µM Etoposide (Sigma) for 48 hours. To induce senescence by ionizing radiation, IMR90 were g-irradiated (6 Gy) and analysed at the indicated times.
Vector construction. pGIPZ-based shRNA targeting GLB1 (V3LHS_361778, V3LHS_361779, V2LHS_232389) were obtained from MRC LMS Genomics core facility.
To generate IMR90 ER:RAS expressing shRNAs against GLB1, lentiviral infections were carried out as described before (Aarts et al. 2017) . Briefly, HEK293T cells were transfected with the lentiviral and packaging vectors using PEI (PEI 2500, Polysciences). Two days after transfection, HEK293T viral supernatants were collected, filtered (0.45 µM), diluted 1/4, supplemented with 4µg/ml polybrene and added to IMR90 ER:RAS cells plated the day before at a density of 1 million cells per 10 cm dish. Four hours later, lentivirus-containing media was replaced with fresh media. Three days after infection, cells were passaged and cultured for three days in the presence of 1µg/ml puromycin (InvivoGen) to select for infected cells.
BrdU incorporation. BrdU incorporation assays were performed as previously described (Georgilis et al. 2018) . Briefly, for BrdU incorporation assays, the cells were incubated with 10 µM BrdU for 16-18 hours before being fixed with 4% PFA (w/v). BrdU incorporation was assessed by Immunofluorescence and High Content Analysis microscopy.
Immunofluorescence staining of cells. Cells were grown in 96-well plates, fixed with 4% PFA (w/v) and stained as previously described (Georgilis et al. 2018) . For SA-b-Galactosidase staining in tissues, frozen sections (6 µm) were fixed in ice-cold 0.5% glutaraldehyde (w/v) solution for 15 min, washed with 1mM MgCl2/PBS (pH 6.0) for 5 min and then incubated with X-Gal staining solution for 16-18 hr at 37°C as previously described (Georgilis et al. 2018) . After the staining, the slides were counterstained with eosin, dehydrated, mounted and analysed by phase-contrast microscopy. SA-b-Gal tissue staining was quantified using ImageJ software (NIH) by measuring the percentage of stained area in each section and multiplying it by its mean intensity value as described before (Tordella et al. 2016) . To exclude the luminal spaces in the lung sections, the percentage of SA-b-Gal positive area was divided by the total lung area, as determined by eosin-positive area using ImageJ (NIH).
Determining senolytic activity. For oncogene-induced senescence experiments, IMR90
ER:RAS or HMEC ER:RAS cells were plated in 96-well dishes and induced to undergo senescence by treating them with 100 nM 4OHT for 6 days. At that point, 1 µM ABT-263 or different concentrations of the galactose-modified pro-drugs were added. In parallel, the same treatments were carried out in IMR90 ER:RAS or HMEC ER:RAS cells treated with DMSO (-4OHT). These cells do not undergo senescence. Cells were fixed at day 9 after 4OHT induction and stained with DAPI (1 µg/ml) for 15 min to assess cell numbers using automated microscopy. Different models of senescence were used to test the senolytic activity of galactose-modified pro-drugs in cell culture in a similar fashion. Briefly, for therapy-induced senescence IMR90 cells were treated with 50 µM etoposide (48h), 0.5 µM doxorubicin (24h) or left untreated, and then kept in drug-free complete media until day 7, when the senolytics were added. Cells were fixed at day 10 after senescence induction. In all senescence types tested, 3-day course of senolytics was applied. The percentage of cell survival was calculated dividing the number of cells after drug treatment by the number of cells treated with vehicle.
High Content Analysis (HCA). IF imaging was carried out using the automated highthroughput fluorescent microscope IN Cell Analyzer 2000 (GE Healthcare) with a 20x objective. Multiple fields within a well were acquired in order to include a minimum of 1,000 cells per sample-well. HCA of the images were processed using the INCell Investigator 2.7.3 software as described previously (Herranz et al. 2015) . Briefly, DAPI served as a nuclear mask hence allowed for segmentation of cells with a Top-Hat method. To detect cytoplasmic staining in cultured cells, a collar of 7-9 µm around DAPI was applied. In samples of cultured cells, a threshold for positive cells was assigned above the average intensity of unstained or negative control sample unless otherwise specified.
IncuCyte analysis. IMR90 ER:RAS cells were plated in 96-well dishes and induced to undergo senescence as previously described. Different concentrations of galactosemodified pro-drug were added as normally. Cell culture media was supplemented with IncuCyte NucLight Rapid Red reagent for cell labelling (Essen Bioscience) and IncuCyte Caspase-3/7 reagent for apoptosis (Essen Bioscience). Four images per well were collected every 2 hr for 3 days using a 10x objective.
Mouse models and drug treatments. For induction of senescence, C57BL/6J mice at of 8-12 weeks of age were exposed to a sublethal dose (6 Gy) of total body irradiation. 8 weeks after, mice were injected with 50nmols of pro-drug (i.v.) or vehicle for 4 consecutive days. Mice were killed 24 h after the last injection. Mice lungs were harvested for RNA extraction, paraffin embedded for immunohistology, or frozen in OCT/ Sucrose 15% (1:1) solution for cryosectioning and SA-b-gal stains. The mice used for all experiments were randomly assigned to control or treatment groups. Both sexes were used throughout the study.
For in vivo treatment, ABT-263 was prepared in ethanol:polyethylene glycol 400:Phosal 50 PG at 10:30:60 as previously described . Mice were gavaged with vehicle Immunofluorescence staining was performed as previously described (Gonzalez-Meljem et al. 2017) . The proportion of β-catenin-accumulating and p21-positive cells was calculated as an index out of the total DAPI-stained nuclei. The proportion of β-catenin-accumulating, cleaved-caspase-3 and p21-positive cells was calculated as an index out of the total DAPIstained nuclei. Over 300,000 DAPI nuclei were counted from ten histological sections per sample, in a total of twelve neoplastic pituitaries.
Statistical analysis. GraphPad Prism 7.0 was used for statistical analysis. Two-tailed Student's t-tests were used to estimate statistically significant differences between two groups. Two-way ANOVA with Tukey's post hoc comparison was used for multiple comparisons. Values are presented as mean ± s.d. unless otherwise indicated. Asterisks (*) always indicate significant differences as follows: ns = not significant, * = P < 0.5, ** = P < 0.01, *** = P < 0.001.
For in vivo studies, mice were randomly assigned to treatment groups. All replicates in this study represent different mice.
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